Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55761 | TTC17 | 052097_1595-all-cells | Human | Prostate | BPH | 3.02e-18 | 5.46e-01 | 0.0972 |
55761 | TTC17 | 052099_1652-all-cells | Human | Prostate | BPH | 7.06e-15 | 5.00e-01 | 0.1038 |
55761 | TTC17 | Dong_P1 | Human | Prostate | Tumor | 6.78e-13 | 6.07e-03 | 0.035 |
55761 | TTC17 | Dong_P3 | Human | Prostate | Tumor | 4.11e-12 | 1.48e-01 | 0.0278 |
55761 | TTC17 | Dong_P4 | Human | Prostate | Tumor | 1.15e-02 | 1.79e-01 | 0.0292 |
55761 | TTC17 | Dong_P5 | Human | Prostate | Tumor | 9.70e-08 | -7.88e-02 | 0.053 |
55761 | TTC17 | GSM5353215_PA_AUG_PB_1B_S2 | Human | Prostate | Tumor | 1.64e-02 | 4.41e-01 | 0.1557 |
55761 | TTC17 | GSM5353216_PA_PB1A_Pool_1_3_S50_L002 | Human | Prostate | Tumor | 4.43e-03 | 6.50e-01 | 0.159 |
55761 | TTC17 | GSM5353220_PA_PB1B_Pool_3_S51_L002 | Human | Prostate | Tumor | 1.03e-03 | 5.55e-01 | 0.1531 |
55761 | TTC17 | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 2.31e-07 | 5.84e-01 | 0.1633 |
55761 | TTC17 | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 3.49e-07 | 5.38e-01 | 0.1608 |
55761 | TTC17 | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 2.16e-03 | 4.71e-01 | 0.1621 |
55761 | TTC17 | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 7.07e-06 | 4.18e-01 | 0.1575 |
55761 | TTC17 | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 3.95e-05 | 3.14e-01 | 0.1545 |
55761 | TTC17 | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 5.42e-04 | 3.78e-01 | 0.1569 |
55761 | TTC17 | P1_S1_AK | Human | Skin | AK | 6.36e-10 | 3.69e-01 | -0.3399 |
55761 | TTC17 | P2_S3_AK | Human | Skin | AK | 1.30e-02 | 1.89e-01 | -0.3287 |
55761 | TTC17 | P4_S8_cSCC | Human | Skin | cSCC | 8.43e-09 | 2.38e-01 | -0.3095 |
55761 | TTC17 | P1_cSCC | Human | Skin | cSCC | 7.06e-17 | 6.34e-01 | 0.0292 |
55761 | TTC17 | P2_cSCC | Human | Skin | cSCC | 3.57e-07 | 2.84e-01 | -0.024 |
Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/TTC17_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/TTC17_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/TTC17_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TTC17_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TTC17_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/TTC17_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TTC17_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/TTC17_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/TTC17_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TTC17_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000701510 | Cervix | CC | actin filament organization | 109/2311 | 442/18723 | 4.92e-13 | 2.45e-10 | 109 |
GO:005125810 | Cervix | CC | protein polymerization | 70/2311 | 297/18723 | 5.20e-08 | 3.11e-06 | 70 |
GO:00081549 | Cervix | CC | actin polymerization or depolymerization | 51/2311 | 218/18723 | 4.05e-06 | 1.05e-04 | 51 |
GO:00300419 | Cervix | CC | actin filament polymerization | 45/2311 | 191/18723 | 1.20e-05 | 2.54e-04 | 45 |
GO:0007015 | Colorectum | AD | actin filament organization | 167/3918 | 442/18723 | 1.65e-16 | 7.94e-14 | 167 |
GO:0008154 | Colorectum | AD | actin polymerization or depolymerization | 90/3918 | 218/18723 | 6.14e-12 | 8.23e-10 | 90 |
GO:0030041 | Colorectum | AD | actin filament polymerization | 81/3918 | 191/18723 | 1.35e-11 | 1.69e-09 | 81 |
GO:0051258 | Colorectum | AD | protein polymerization | 112/3918 | 297/18723 | 1.85e-11 | 2.27e-09 | 112 |
GO:00070151 | Colorectum | SER | actin filament organization | 134/2897 | 442/18723 | 1.39e-15 | 5.70e-13 | 134 |
GO:00081541 | Colorectum | SER | actin polymerization or depolymerization | 77/2897 | 218/18723 | 3.50e-13 | 1.19e-10 | 77 |
GO:00300411 | Colorectum | SER | actin filament polymerization | 70/2897 | 191/18723 | 5.39e-13 | 1.65e-10 | 70 |
GO:00512581 | Colorectum | SER | protein polymerization | 91/2897 | 297/18723 | 2.72e-11 | 5.06e-09 | 91 |
GO:00070152 | Colorectum | MSS | actin filament organization | 146/3467 | 442/18723 | 1.16e-13 | 2.67e-11 | 146 |
GO:00081542 | Colorectum | MSS | actin polymerization or depolymerization | 79/3467 | 218/18723 | 4.14e-10 | 3.49e-08 | 79 |
GO:00300412 | Colorectum | MSS | actin filament polymerization | 71/3467 | 191/18723 | 8.77e-10 | 6.92e-08 | 71 |
GO:00512582 | Colorectum | MSS | protein polymerization | 97/3467 | 297/18723 | 2.98e-09 | 2.07e-07 | 97 |
GO:00070154 | Colorectum | FAP | actin filament organization | 125/2622 | 442/18723 | 1.97e-15 | 3.03e-12 | 125 |
GO:00081544 | Colorectum | FAP | actin polymerization or depolymerization | 60/2622 | 218/18723 | 1.15e-07 | 7.43e-06 | 60 |
GO:00300414 | Colorectum | FAP | actin filament polymerization | 53/2622 | 191/18723 | 4.65e-07 | 2.46e-05 | 53 |
GO:00512584 | Colorectum | FAP | protein polymerization | 73/2622 | 297/18723 | 7.11e-07 | 3.32e-05 | 73 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TTC17 | SNV | Missense_Mutation | novel | c.2908G>T | p.Ala970Ser | p.A970S | Q96AE7 | protein_coding | tolerated(0.38) | possibly_damaging(0.551) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
TTC17 | SNV | Missense_Mutation | novel | c.3082A>G | p.Lys1028Glu | p.K1028E | Q96AE7 | protein_coding | tolerated(0.18) | probably_damaging(0.98) | TCGA-A2-A3XY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD |
TTC17 | SNV | Missense_Mutation | | c.2881G>T | p.Asp961Tyr | p.D961Y | Q96AE7 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
TTC17 | SNV | Missense_Mutation | | c.412N>T | p.Asp138Tyr | p.D138Y | Q96AE7 | protein_coding | deleterious(0.02) | possibly_damaging(0.736) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TTC17 | SNV | Missense_Mutation | novel | c.3080N>G | p.Val1027Gly | p.V1027G | Q96AE7 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AO-A1KP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | SD |
TTC17 | SNV | Missense_Mutation | | c.1552G>A | p.Glu518Lys | p.E518K | Q96AE7 | protein_coding | tolerated(0.58) | benign(0.106) | TCGA-AR-A251-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
TTC17 | SNV | Missense_Mutation | | c.334N>T | p.Pro112Ser | p.P112S | Q96AE7 | protein_coding | tolerated(0.28) | benign(0.34) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TTC17 | SNV | Missense_Mutation | | c.751N>G | p.Arg251Gly | p.R251G | Q96AE7 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-C8-A134-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
TTC17 | SNV | Missense_Mutation | rs765970018 | c.1429N>A | p.Val477Ile | p.V477I | Q96AE7 | protein_coding | tolerated(0.39) | benign(0.06) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
TTC17 | insertion | Frame_Shift_Ins | novel | c.2137_2138insTATTATATATTAGTCTTTT | p.Arg713IlefsTer20 | p.R713Ifs*20 | Q96AE7 | protein_coding | | | TCGA-A8-A07L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | | CR |